

**AIDS PHARMACEUTICAL ASSISTANCE-
LOCAL PHARMACEUTICAL ASSISTANCE PROGRAM**

Norfolk Transitional Grant Area
Grant Year 2020/21



Service Category Definition – Local Pharmaceutical Assistance Program

(HIV/AIDS Bureau Policy Clarification Notice #16-02, Revised 10/22/2018)

Local Pharmaceutical Assistance Program (LPAP) is operated by a HRSA RWHAP Part A or B (non-ADAP) recipient or subrecipient as a supplemental means of providing ongoing medication assistance when an HRSA RWHAP ADAP has a restricted formulary, waiting list and/or restricted financial eligibility criteria.

HRSA RWHAP Parts A or B recipients using the LPAP to provide AIDS Pharmaceutical Assistance must establish the following:

- Uniform benefits for all enrolled clients throughout the service area
- A recordkeeping system for distributed medications
- An LPAP advisory board
- A drug formulary that is
 - Approved by the local advisory committee/board and
 - Consists of HIV-related medications not otherwise available to clients due to the elements mentioned above
- A drug distribution system
- A client enrollment and eligibility determination process that includes screening for HRSA RWHAP ADAP and LPAP eligibility with rescreening at minimum of every six months
- Coordination with the state’s HRSA RWHAP Part B ADAP
 - A statement of need should specify restrictions of the state HRSA RWHAP ADAP and the need for the LPAP
- Implementation in accordance with requirements of the HRSA 340 B Drug Pricing Program (including the Prime Vendor Program)

AIDS PHARMACEUTICAL ASSISTANCE- LOCAL PHARMACEUTICAL ASSISTANCE PROGRAM

Norfolk Transitional Grant Area
Grant Year 2020/21



Personnel Qualifications

The facility must be licensed by the Virginia Board of Pharmacy as well as the individuals providing AIDS Pharmaceutical Assistance-LPAP, which must be properly licensed and certified to distribute medication in the State of Virginia.

All Pharmacists and pharmacy technicians must be registered in the state of Virginia and must complete approved continuing education (CE) as determined by the Virginia Board of Pharmacy.

All services provided must be in compliance with national and state practice laws, include evidence-based clinical decisions that are informed by state and federal laws and pharmacy governing bodies.

Provider Responsibility

- Provide to the Part A grantee, on request, documentation that the LPAP program meets HRSA/HAB requirements.
- Maintain documentation, and make available to the Part A grantee on request, proof of client LPAP eligibility that includes HIV status, residency, medical necessity, and low income status as defined by the EMA/TGA based on a specified percent of the Federal Poverty Level (FPL).
- Provide reports to the Part A program of number of individuals served and the medications provided

**AIDS PHARMACEUTICAL ASSISTANCE-
LOCAL PHARMACEUTICAL ASSISTANCE PROGRAM**

Norfolk Transitional Grant Area
Grant Year 2020/21



Norfolk TGA Care Continuum Performance Measures

(Appendix B: Norfolk TGA Care Continuum Performance Measures)

Standard	Measure
A client enrollment and eligibility determination process that includes screening for ADAP and LPAP eligibility with rescreening every six months	Documentation of completed enrollment and eligibility for all clients under 500% of the FPL
A LPAP advisory board	Documentation of participation in the TGA LPAP advisory board
A drug formulary approved by the local advisory local advisory committee/board that consist of HIV-related medications not otherwise available to clients due to ADAP restricted formulary, waitlist or restricted financial eligibility.	Documentation and use of the approved formulary.
A recordkeeping system for distributed medications	Documentation via CAREWare and prescription/patient management system that provides the number of individuals and the medications dispersed
A drug distribution system that meets that 340B Drug Program Pricing, Prime Vendor and/or Alternate Methods Project requirements in order to ensure best pricing to maximize resources. (HRSA HAB Program Letter August 29, 2013.)	Documentation that the system provides medications approved by the Advisory Board at that best price possible

HRSA/HAB Performance Measure: HIV Viral Load Suppression (NQF#: 2082)				
Performance Measure/Description	Numerator	Denominator	Exclusions	Goal
Percentage of patients who have a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year.	The number of patients with a viral load <200 copies/mL at last test during the 12-month measurement period.	All patients with at least one AIDS pharmaceutical assistance visit during the 12-month measurement period.	None	85%

Approved
Draft Revision 2/20/2020

